The safety of venetoclax, ibrutinib, prednisone, obinutuzumab, and lenalidomide (ViPOR) in R/R MCL

BTK inhibitors for R/R MCL: current uses and insights from the ViPOR studyПодробнее

SYMPATICO: safety and efficacy of ibrutinib plus venetoclax for R/R MCLПодробнее

ViPOR regimen for R/R B-cell lymphomaПодробнее

Does upfront treatment with venetoclax, lenalidomide, and rituximab enhance tumor responses in MCL?Подробнее

Selecting BTK inhibitors for patients with MCLПодробнее

Dr. Rule on the Combination of Venetoclax and Ibrutinib in MCLПодробнее

Obinutuzumab plus venetoclax in early R/R DLBCLПодробнее

OAsIs trial update: ibrutinib, venetoclax plus obinutuzumab in newly diagnosed MCLПодробнее

Venetoclax, lenalidomide and rituximab in R/R MCLПодробнее

TRIANGLE: ibrutinib with SOC or as a substitute to autologous transplantation in first-line MCLПодробнее

Real-world outcomes of brexu-cel in patients with R/R MCLПодробнее

IMPROVE study update: safety and efficacy of venetoclax retreatment in R/R CLLПодробнее

Dr. O'Connor on Acalabrutinib Versus Ibrutinib in MCLПодробнее

The role of ibrutinib in DLBCL and the value of next-generation BTK inhibitorsПодробнее

Venetoclax + pirtobrutinib for MCL resistant to CAR-T and targeted therapiesПодробнее

Optimizing the combination of ibrutinib plus venetoclax in CLLПодробнее

Key novel agents for relapsed diffuse large B-cell lymphomaПодробнее

CLARITY: a Phase 2 trial using venetoclax and ibrutinibПодробнее

Safety analysis of the BCL-2 inhibitor venetoclax for CLLПодробнее